Showing results (141-150 of 697) with videos related to
Sort By:
Pageof 70
Bone Marrow Transplantation|June 11, 2020
Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosisNadine Abdallah, Surbhi Sidana, Angela Dispenzieri, et al.The American Journal of Medicine|October 25, 2011
Cardiac amyloidosis: a practical approach to diagnosis and managementPrashant Kapoor, Thenappan Thenappan, Ekta Singh, et al.Indian Journal of Pathology & Microbiology|April 18, 2014
C-reactive protein in patients with Guillain Barré syndromeChetana Vaishnavi, Prashant Kapoor, Chitra Behura, et al.Current Hematologic Malignancy Reports|February 17, 2018
Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management StrategiesKristen B McCullough, Miriam A Hobbs, Jithma P Abeykoon, et al.Leukemia Research|October 6, 2014
Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001Vijay Ramakrishnan, Teresa Kimlinger, Michael Timm, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2002
Promising preclinical activity of 2-methoxyestradiol in multiple myelomaDavid Dingli, Michael Timm, Stephen J Russell, et al.Hematology/Oncology Clinics of North America|September 13, 2014
Monoclonal gammopathy of undetermined significance and smoldering multiple myelomaRobert A Kyle, Jesus F San-Miguel, Maria-Victoria Mateos, et al.Blood Cancer Journal|December 6, 2022
Second- and third-line treatment strategies in multiple myeloma: a referral-center experienceSarah Goldman-Mazur, Alissa Visram, S Vincent Rajkumar, et al.Mayo Clinic Proceedings|June 1, 2010
Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapiePrashant Kapoor, Rafael Fonseca, S Vincent Rajkumar, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2013
Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosisTaxiarchis V Kourelis, Shaji K Kumar, Morie A Gertz, et al.Pageof 70